Caprock Group LLC Trims Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Caprock Group LLC decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 79.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,637 shares of the company's stock after selling 45,443 shares during the period. Caprock Group LLC's holdings in Elanco Animal Health were worth $141,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ELAN. JPMorgan Chase & Co. increased its stake in shares of Elanco Animal Health by 76.6% in the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after purchasing an additional 4,361,799 shares in the last quarter. State Street Corp grew its stake in Elanco Animal Health by 2.6% in the third quarter. State Street Corp now owns 9,912,693 shares of the company's stock worth $145,617,000 after purchasing an additional 255,084 shares in the last quarter. Geode Capital Management LLC increased its holdings in Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock worth $115,623,000 after purchasing an additional 65,303 shares during the period. The Manufacturers Life Insurance Company raised its position in Elanco Animal Health by 6.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company's stock valued at $93,803,000 after purchasing an additional 394,921 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Elanco Animal Health by 19.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company's stock worth $58,875,000 after buying an additional 646,522 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ELAN shares. Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Stifel Nicolaus cut their target price on Elanco Animal Health from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Barclays boosted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 8th. UBS Group began coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a "buy" rating and a $18.00 price target on the stock. Finally, Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $16.29.

Elanco Animal Health Trading Down 0.5 %

Elanco Animal Health stock traded down $0.06 during trading on Tuesday, reaching $11.42. The company had a trading volume of 3,376,623 shares, compared to its average volume of 4,715,201. Elanco Animal Health Incorporated has a 12-month low of $11.11 and a 12-month high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock's 50 day moving average price is $11.99 and its two-hundred day moving average price is $13.18. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.69 and a beta of 1.42.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.